Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

561

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

March 31, 2033

Study Completion Date

March 31, 2033

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

Surabgene Lomparvovec (ABBV-RGX-314)

subretinal injection

DRUG

Ranibizumab Control

intravitreal injection